Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China. Its lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC), as well as for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

Sector

Healthcare

Industry

Biotechnology

CEO

Du, Jinhao

Employees

1,417

Website

www.allist.com.cn

IPO Date

2020-12-02

Headquarters

No. 268 Lingxiaohua Road, Zhoupu Town, Pudong New Area, Shanghai 201318, China

Socials

NEWSLETTER

View Data Providers

NEWSLETTER

View Data Providers

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

Shanghai Allist Pharmaceuticals 688578

Shanghai Allist Pharmaceuticals Earnings Call Summary

Shanghai Allist Pharmaceuticals Earnings

Transcripts

Events

About Shanghai Allist Pharmaceuticals Co., Ltd.

Shanghai Allist Pharmaceuticals
688578